{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [3, 5], "question": "How did the adjusted EBITDA change from 2022 to 2023 for both the Degree Program Segment and the Alternative Credential Segment?", "prediction": "The provided chunks do not contain information on the adjusted EBITDA change for the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023. The adjusted EBITDA is mentioned, but only the definition and its use as a key metric are provided, without segment-specific data for 2022 and 2023.", "ground_truth": "The adjusted EBITDA for the Degree Program Segment increased by $34 million from $180.7 million in 2022 to $214.7 million in 2023, while the Alternative Credential Segment's negative adjusted EBITDA improved by $11.7 million from -$55.6 million in 2022 to -$43.9 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [1, 4], "question": "How did the level of impairment charges for goodwill change in the Degree Program Segment and Alternative Credential Segment from 2022 to 2023?", "prediction": "In 2022, the Alternative Credential Segment had impairment charges of $78,991,000, while the Degree Program Segment had none. In 2023, the Alternative Credential Segment had impairment charges of $79,471,000, and the Degree Program Segment still had none, but $62.8 million of the charges in 2023 were recorded in the 4th quarter.", "ground_truth": "In the Degree Program Segment, there were no impairment charges for goodwill in either 2022 or 2023, whereas in the Alternative Credential Segment, goodwill impairment charges increased from $78.991 million in 2022 to $79.471 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [0, 3], "question": "How did Full Course Equivalent (FCE) enrollments change in both the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023?", "prediction": "In the Degree Program Segment, FCE enrollments decreased by 39,061, or 16.7%. In the Alternative Credential Segment, FCE enrollments in boot camp offerings decreased by 6%, while FCE enrollments in executive education offerings increased by 8%.", "ground_truth": "FCE enrollments decreased by 16.7% in the Degree Program Segment from 233,635 in 2022 to 194,574 in 2023, while they increased by 4.5% in the Alternative Credential Segment from 93,471 in 2022 to 97,647 in 2023."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 2], "question": "What were the main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021?", "prediction": "The main factors contributing to the decline in gross profit were:\n\n1. Divestitures ($33.5 million)\n2. Cost inflation\n3. Supply chain pressures\n4. Lower sales volumes in the dental market \n\nThese factors resulted in a $49.5 million decrease in gross profit for the year ended December 31, 2022, compared to 2021.", "ground_truth": "The decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 was primarily due to divestitures, lower sales volumes in the dental market, and inflationary cost pressures, as indicated by the financial data provided."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [2, 5], "question": "How did the impairment charges on property and equipment and the amortization expense related to intangible assets change from 2021 to 2022?", "prediction": "Impairment charges on property and equipment decreased from $788 in 2021 to $18 in 2022. Amortization expense related to intangible assets can be inferred to have decreased, as the net intangible assets decreased from $45,835 in 2021 to $84,782 in 2022, but this is due to an increase in gross intangible assets. A more precise calculation of amortization expense is not provided, but the decrease in accumulated amortization from $116,208 to $127,020 (increase in absolute value) over the intangible assets with finite lives suggests a significant amortization expense in 2022.", "ground_truth": "The impairment charges decreased from $788,000 in 2021 to $18,000 in 2022, while amortization expense increased from $10,469,000 in 2021 to $15,480,000 in 2022."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 1], "question": "How did the operating income for Healthcare Solutions and Industrial Solutions segments change from 2021 to 2022?", "prediction": "The operating income for Healthcare Solutions decreased by $43.5 million (from $69.4 million to $25.8 million) and for Industrial Solutions decreased by $25.7 million (from $48.6 million to $22.8 million) from 2021 to 2022.", "ground_truth": "The operating income for Healthcare Solutions decreased by $43.5 million from $69.4 million in 2021 to $25.9 million in 2022, while for Industrial Solutions it decreased by $25.7 million from $48.6 million in 2021 to $22.8 million in 2022."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [2, 4], "question": "How much interest income did Block, Inc. earn from customer funds in 2023, and how did it compare to the previous years?", "prediction": "The provided chunks do not contain information about the interest income earned from customer funds in 2023 or any other year.", "ground_truth": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds, which was immaterial in both 2022 and 2021."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 2], "question": "How did the organizational structure change with respect to Block, Inc's management reporting in the fourth quarter of 2023 affect the allocation of BNPL platform financial results?", "prediction": "The change in organizational structure moved the business activities and management of the BNPL platform fully under Cash App, resulting in the allocation of BNPL platform financial results solely to the Cash App segment.", "ground_truth": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure, moving the business activities and management of its BNPL platform fully under the Cash App segment, thus ceasing the previous practice of allocating 50% of revenue and gross profit from the BNPL platform to both the Square and Cash App segments."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 4], "question": "How did the classification of consumer receivables and their allowance for credit losses change from January 31, 2022 to December 31, 2023?", "prediction": "The allowance for credit losses increased from $151.3 million (as of January 31, 2022, and also December 31, 2022) to $185.3 million as of December 31, 2023. Additionally, the proportion of Classified consumer receivables (those over 60 days past due) remained relatively small, with an amortized cost of $0.1 billion as of December 31, 2023, compared to a total amortized cost of consumer receivables of $2.629 billion.", "ground_truth": "The consumer receivables classified as 'Pass' increased to $2.5 billion with $185.275 million in credit loss allowance by December 31, 2023, from the time of Afterpay's acquisition in January 2022 where the beginning allowance was $115.552 million."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [4, 5], "question": "What was the percentage change in the net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023?", "prediction": "To calculate the percentage change, we need the values from chunk 1: \nNet property and equipment (2022): $159,432\nNet property and equipment (2023): $144,718\n\nPercentage change = ((144,718 - 159,432) / 159,432) * 100\nPercentage change = (-14,714 / 159,432) * 100\nPercentage change ≈ -9.23%\n\nThe net property and equipment value decreased by approximately 9.23% between December 31, 2022, and December 31, 2023.", "ground_truth": "The net property and equipment values decreased by approximately 9.2% from $159,432,000 on December 31, 2022, to $144,718,000 on December 31, 2023."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [1, 3], "question": "What were the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements?", "prediction": "The chunks provided do not explicitly state the primary factors affecting C.H. Robinson's financial performance in 2023. However, they do mention the company's revenue, logistics services, and goodwill impairment testing. According to chunk 0, the company's consolidated total revenues were $17.6 billion in 2023, and chunk 1 mentions that the company handled approximately 19 million shipments and worked with over 90,000 customers. These may be indicative of the company's financial performance, but the chunks do not provide a clear analysis of the primary factors affecting it.", "ground_truth": "C.H. Robinson's financial performance in 2023 was primarily affected by weak freight demand and excess carrier capacity leading to reduced net income and operating cash flow, alongside declines in transportation rates."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [3, 4], "question": "How did the revenue recognition policy related to in-transit shipments change from December 31, 2022, to December 31, 2023?", "prediction": "The amount of revenue recognized for contracts where the transit period was partially complete declined significantly at December 31, 2023, compared to December 31, 2022, from $257.6 million to $189.9 million, driven by macroeconomic and industry factors impacting the cost of purchased transportation.", "ground_truth": "The revenue for contracts where the transit period was partially complete declined from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023, due to macroeconomic and industry factors impacting transportation costs."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 5], "question": "What was the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, and how does it compare to the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of the same date?", "prediction": "The total stock-based compensation expense for the year ended December 31, 2023, was $231.3 million. In comparison, the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of December 31, 2023, was approximately $354.8 million, which is expected to be recognized over a weighted average period of 2.42 years.", "ground_truth": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million, while the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 4], "question": "How did the research and development expenses change from 2022 to 2023 compared to sales and marketing expenses, and what were the main reasons for these changes?", "prediction": "Research and development expenses increased by $32.5 million (8.2%) from 2022 to 2023, primarily due to increased personnel expenses and costs related to MCED and MRD research activities. In contrast, sales and marketing expenses decreased, primarily due to decreases in direct marketing costs, professional fees, and personnel expenses. However, the exact decrease in sales and marketing expenses is not provided in the given chunks.", "ground_truth": "Research and development expenses increased by $32.5 million due to higher personnel expenses and facility costs, while sales and marketing expenses decreased by $118.9 million primarily due to reduced marketing costs and a realignment of the sales force."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [1, 3], "question": "How did Exact Sciences Corporation’s cash and cash equivalents at the end of 2023 compare with their amount at the beginning of the year, and what was the cause of this change based on their cash flow activities?", "prediction": "Exact Sciences Corporation's cash and cash equivalents increased from $242,790 at the beginning of 2023 to $609,675 at the end of 2023. This increase was primarily due to net cash provided by financing activities ($159,766) and operating activities ($156,100), partially offset by a decrease in investing activities.", "ground_truth": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million by the end of the year, driven by positive net cash provided by operating activities and an increase in net cash provided by financing activities, including proceeds from the issuance of convertible notes."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 1], "question": "How much did Esperion's net product sales increase from 2022 to 2023, and how much did their collaboration revenue increase within the same period?", "prediction": "Esperion's net product sales increased by $22.4 million (from $55.9 million to $78.3 million), and their collaboration revenue increased by $18.4 million (from $19.6 million to $38.0 million) from 2022 to 2023.", "ground_truth": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, while their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [1, 4], "question": "How did Esperion Therapeutics, Inc.'s net loss change from 2022 to 2023 and what were the factors contributing to this change?", "prediction": "Esperion Therapeutics, Inc.'s net loss decreased from $233,659 in 2022 to $209,248 in 2023. The main factors contributing to this change were a decrease in research and development expenses, and an increase in total revenues, partially offset by an increase in selling, general, and administrative expenses.", "ground_truth": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, primarily due to increased net product sales and collaboration revenue, partially offset by increased selling, general, and administrative expenses."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 2], "question": "What changes occurred in the net product sales of NEXLETOL and NEXLIZET from 2022 to 2023, and how did the collaboration revenue compare during the same period?", "prediction": "Net product sales of NEXLETOL and NEXLIZET increased by $22.4 million (from $55.9 million to $78.3 million) from 2022 to 2023. Collaboration revenue also increased by $18.4 million (from $19.6 million to $38.0 million) during the same period.", "ground_truth": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, while collaboration revenue also grew from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [2, 5], "question": "What was the percentage change in the Company's total revenue from the Property & Casualty insurance vertical from 2021 to 2023, compared to the Health insurance vertical for the same period?", "prediction": "To determine the percentage change, we need data from 2021, which is not provided. However, we can calculate the percentage change from 2022 to 2023.\n\nFor Property & Casualty insurance: -26.8% (from $224,366 to $164,234)\nFor Health insurance: -0.6% (from $187,392 to $186,275)\n\nNote: The data for 2021 is not available to calculate the exact percentage change from 2021 to 2023.", "ground_truth": "The Company's total revenue from Property & Casualty insurance vertical decreased by 60.7% from $417,715,000 in 2021 to $164,234,000 in 2023, while the Health insurance vertical saw a 5.6% increase from $176,459,000 in 2021 to $186,275,000 in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [0, 5], "question": "How did the revenue from Open Marketplace transactions compare to Private Marketplace transactions in the year ended December 31, 2023?", "prediction": "The revenue from Open Marketplace transactions was $378,730 (63.8% of total Transaction Value), while the revenue from Private Marketplace transactions was $214,708 (36.2% of total Transaction Value) for the year ended December 31, 2023.", "ground_truth": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730,000 in revenue, which was significantly higher than Private Marketplace transactions which generated $9,419,000."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [3, 4], "question": "How did the decrease in P&C insurance revenue contribute to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022?", "prediction": "The decrease in P&C insurance revenue contributed $60,132 (or 26.8%) to the overall decline in total revenue, which was $70,923 (or 15.4%) for the year ended December 31, 2023 compared to 2022.", "ground_truth": "The P&C insurance revenue decreased by $60.1 million in 2023, primarily due to reduced customer acquisition spending by P&C carriers, contributing significantly to the overall decline in total revenue by $70.9 million compared to 2022."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [2, 4], "question": "What are the potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations?", "prediction": "The potential effects of regulatory changes on Mind Medicine's EU operations include:\n\n* Reduced data exclusivity period from 8 to 6 years, potentially allowing generic or biosimilar products to enter the market sooner.\n* Changes to medical device regulations, such as the MDR, which may impact the development, approval, and marketing of Mind Medicine's medical devices in the EU.\n* Brexit-related uncertainties and changes to UK regulations, which may affect Mind Medicine's access to the UK market and require additional registrations or certifications.\n* Increased regulatory burdens and costs associated with complying with EU and UK regulations.", "ground_truth": "Regulatory changes in the EU, such as the proposal to reduce data exclusivity from eight to six years and the MDR governing medical devices, could affect Mind Medicine's product development timelines and compliance requirements, impacting their ability to market products efficiently in the EU."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [3, 4], "question": "Between December 31, 2022, and December 31, 2023, how much of the equity securities registered under the shelf registration statement was issued by the company?", "prediction": "$0.2 million was issued, as the available amount decreased from $100.0 million to $99.8 million.", "ground_truth": "Between December 31, 2022, and December 31, 2023, the company issued $0.2 million of equity securities, as the availability decreased from $100.0 million to $99.8 million."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [1, 3], "question": "What are some potential consequences mentioned in the financial statements if the company fails to comply with controlled substance laws and regulations when developing its product candidates?", "prediction": "Some potential consequences mentioned include:\n\n* Significant fines, penalties, and administrative sanctions\n* Convictions, settlements, or criminal charges\n* Disgorgement of profits, cessation of business activities, or divestiture\n* Negative impact on reputation, financial position, and ability to conduct business\n* Limitations on commercialization and revenue generation\n* Potential prohibition of investments from foreign jurisdictions.", "ground_truth": "Failure to comply with controlled substance laws and regulations may result in increased costs, enforcement actions, regulatory scrutiny, potential litigation, and criminal prosecution, which could delay or prevent product development and commercialization."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [0, 2], "question": "What percentage of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment, and what challenges does this concentration pose?", "prediction": "For fiscal year 2024, a single customer within the Compute & Networking segment represented 13% of NVIDIA's total revenue. This concentration poses challenges, including the risk of losing revenue if the customer reduces or cancels purchases, and potential disruptions to NVIDIA's operating results.", "ground_truth": "Sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, posing challenges like potential revenue impact from losing or being unable to sell to such major customers due to trade restrictions."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 5], "question": "What was the change in NVIDIA's net income from January 29, 2023, to January 28, 2024, and how does this compare to the change in revenue for the same period?", "prediction": "The change in NVIDIA's net income from January 29, 2023, to January 28, 2024, was an increase of $25,392 million ($29,760 - $4,368). The change in revenue for the same period was an increase of $33,948 million ($60,922 - $26,974). The net income increase was approximately 75% of the revenue increase.", "ground_truth": "NVIDIA's net income increased from $4.37 billion on January 29, 2023, to $29.76 billion on January 28, 2024, while revenue increased from $26.97 billion to $60.92 billion during the same period."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 2], "question": "What percentage of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, and how does this demonstrate a risk presented in the Risk Factors?", "prediction": "13% of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment. This demonstrates a concentration of revenue risk, as presented in the Risk Factors, where the loss of a major customer could significantly impact the company's financial performance.", "ground_truth": "In fiscal year 2024, 13% of NVIDIA's revenue came from a single customer in the Compute & Networking segment, illustrating the risk of revenue concentration from limited partners and distributors, as mentioned in the Risk Factors."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [1, 3], "question": "How did Paratek's financial position affect their ability to utilize net operating loss carryforwards after the merger, and what was the impact on regulatory operations?", "prediction": "After the merger, Paratek's financial position was affected by ownership change limitations under Section 382 of the Internal Revenue Code, which restricted their ability to utilize net operating loss carryforwards. As a result, they may not be able to recognize the benefits of federal and state deferred tax assets, potentially having a material adverse effect on cash flow and results of operations.", "ground_truth": "Paratek's financial position was impacted by ownership changes from the merger that limited the use of net operating loss carryforwards, which could materially affect cash flow and operations as government regulations require cost compliance in various areas."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [3, 4], "question": "How did the full-year net product revenue change for Paratek Pharmaceuticals' NUZYRA from 2021 to 2022, and what was the impact on the company's net loss for the same period?", "prediction": "The full-year net product revenue for Paratek Pharmaceuticals' NUZYRA increased by $30.7 million (or 29%) from $106.1 million in 2021 to $136.8 million in 2022. Despite this increase, the company's net loss increased by $4.5 million from $59.1 million in 2021 to $63.6 million in 2022, primarily due to higher operating expenses.", "ground_truth": "The net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, while the net loss increased from $59.1 million in 2021 to $63.6 million in 2022."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [0, 2], "question": "What are the factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements?", "prediction": "The factors affecting the commercialization success of NUZYRA in the U.S. include:\n\n1. Ability to secure sufficient starting materials and maintain commercial manufacturing arrangements.\n2. Building and maintaining internal sales, distribution, and marketing capabilities.\n3. Securing widespread acceptance from physicians, healthcare payors, and patients.\n4. Proper pricing and obtaining coverage and reimbursement from governmental authorities and private health insurers.\n5. Managing costs and expenses commensurate with projected growth.\n6. Establishing and maintaining collaborations with third parties for commercialization.\n7. Retaining effective commercial personnel and training sales personnel.\n8. Equipping sales personnel with effective materials and addressing potential complications due to COVID-19 or other outbreaks.", "ground_truth": "The success of NUZYRA's commercialization in the U.S. depends on securing starting materials, maintaining manufacturing arrangements, producing sufficient quantities, building sales and marketing capabilities, gaining product acceptance, obtaining sufficient reimbursement, and maintaining compliance with FDA requirements as mentioned in the financial statements."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 2], "question": "What were the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023?", "prediction": "The factors contributing to the change in automotive sales revenue from 2022 to 2023 were:\n\n* Increase in deliveries (17% revenue growth)\n* Partially offset by a decrease in the average selling price of used vehicles\n\nThe factors contributing to the decrease in automotive gross margin from 28.5% to 19.4% from 2022 to 2023 were:\n\n* Lower average selling price\n* Partially offset by:\n\t+ Decrease in average combined cost per unit due to sales mix, lower inbound freight, and lower material costs\n\t+ Lower manufacturing costs from better fixed cost absorption\n\t+ IRA manufacturing credits earned", "ground_truth": "Automotive sales revenue increased by $11.30 billion due to a rise in Model 3 and Model Y deliveries, while the gross margin decreased from 28.5% to 19.4% due to lower average selling prices and increased costs."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [3, 5], "question": "How did Tesla's short-term investments and inventory change from December 31, 2022, to December 31, 2023?", "prediction": "Short-term investments increased from $5,932 million to $12,696 million. Inventory increased by $1,195 million (from $6,465 million decrease in 2022 to $1,195 million decrease in 2023, implying an increase of $5,270 million, but the actual 2022 value is not provided, only the change).", "ground_truth": "Tesla's short-term investments increased from $5,932 million in 2022 to $12,696 million in 2023, while inventory increased from $12,839 million in 2022 to $13,626 million in 2023."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 5], "question": "How do the commitments for capital expenditure and tax revenues in the state of New York compare to those in Shanghai, China for Tesla as of December 31, 2023?", "prediction": "As of December 31, 2023, Tesla's commitments are:\n- In New York: $5 billion in combined capital, operational expenses, and costs over 10 years, with employment targets and annual \"program payments\" of $41 million if targets are not met.\n- In Shanghai, China: RMB 14.08 billion (approximately $2 billion USD, but exact conversion not provided) in capital expenditures by the end of 2023 (already achieved), and RMB 2.23 billion of annual tax revenues starting at the end of 2023.", "ground_truth": "As of December 31, 2023, Tesla committed to $5 billion in combined expenditures and costs in New York state by the end of 2029, while in Shanghai, China, Tesla committed to RMB 14.08 billion in capital expenditures and RMB 2.23 billion in annual tax revenues by the end of 2023, both of which have been achieved."}
